Physician profile
Amy C Roy
NPI 1538166186
$3,092.14
in general payments reported to CMS, 2019-2025
21 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $514 · 2023: $599 · 2024: $919 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,099.38 | 2021-2025 | |
| Abbott Laboratories | $260.85 | 2021-2024 | Proclaim |
| Nevro Corp. | $248.98 | 2023-2024 | Senza |
| Averitas Pharma INC. | $221.56 | 2023-2024 | Qutenza |
| Collegium Pharmaceutical, INC. | $181.63 | 2021-2024 | Belbuca, Xtampza |
| Biodelivery Sciences International, INC. | $133.28 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $129.00 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $118.61 | 2021-2025 | Ajovy |
| Painteq LLC | $97.46 | 2023-2024 | Painteq |
| Fidia Pharma USA INC. | $95.25 | 2021-2024 | Hymovis |
| Amgen INC. | $92.08 | 2021-2022 | |
| Lundbeck LLC | $88.95 | 2023 | Vyepti |
| Allergan, INC. | $68.62 | 2021-2022 | |
| Lilly USA, LLC | $55.97 | 2021-2022 | |
| Pfizer INC. | $54.85 | 2021-2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $42.48 | 2021 | |
| Boston Scientific Corporation | $39.06 | 2022-2024 | Infinion 16 |
| Orexo US, INC. | $19.60 | 2025 | Zubsolv |
| Pacira Pharmaceuticals Incorporated | $16.17 | 2021 | |
| Tonix Medicines, INC. | $14.52 | 2025 | Tonmya |
| Merit Medical Systems INC | $13.84 | 2023 | Stabilit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.